How prior authorization rations care without denying it
Managed care plans are quietly restructuring access to medication. Coverage is not being reduced. Eligibility is not being narrowed. The medications remain on the formulary. What is being added — under language about “service authorization” and “review timeframes” — is a process. The process is what does the work.
A notice arrived from Independent Health this month explaining changes to its prior authorization procedures effective April 1, 2026. Standard prior authorization decisions, the notice states, will be made within three work days of when the plan has all the information it needs, but no later than seven days after the request is received. A subordinate clause carries most of the weight: the plan will tell the requester by the seventh day if it needs more information.
That clause is the design.
The seven-day clock does not run toward a decision. It runs toward a request for additional documentation. When that request arrives, the patient — or, more accurately, the patient’s prescribing provider, who is presumed to have institutional capacity the patient does not — is responsible for producing whatever additional information has been deemed insufficient. The clock then resets. There is no upper limit on how many cycles the process can sustain. The notice does not contain one because the structure does not require one. Delay is not the failure mode. Delay is the mechanism.
The Form as Case File
The accompanying NYS Medicaid Prior Authorization Request Form For Prescriptions makes the design concrete. It is not a request. It is a case file.
To approve a single medication, the form requires: the patient’s diagnosis with ICD-10 code; the medication’s strength, frequency, quantity, and refill count; route of administration; whether the prescriber will also administer the drug; whether the use is FDA-approved; if not, whether the use is supported by official compendia such as AHFS DI or DRUGDEX; whether the patient has experienced treatment failure with formulary alternatives, including drug, dose, route, frequency, date range, and outcome for each prior medication; whether the patient has a documented history of successful control on a non-formulary drug for which transition to a formulary drug is medically contraindicated; relevant lab results, tests, and diagnostic studies; and a written rationale for medical necessity.
This is not a check against fraud. It is the construction of an evidentiary record sufficient to defend the authorization against subsequent review. The labor of constructing that record is offloaded onto the prescriber. In practice, when prescribers’ offices are overloaded, that labor migrates again to the patient, who is asked to call, follow up, retrieve records, push for resubmission, and absorb the gap in care while the documentation is assembled.
What Page Two Asks For
The second page of the form contains the most analytically interesting passage. Under instructional information for prior authorization, the plan suggests providers consider supplying “as applicable & when available” additional context including HCPCS codes, transition-of-care information from hospitals or residential treatment facilities, and a category labeled “Life Situations Information,” defined as “foster care transition, homelessness, poly-substance abuse and history of poor medication adherence.”
These are not eligibility criteria. They are not required. They are recommended supplements to the case for medical necessity.
The implication is that the strength of a prescription request can be improved by disclosing more of a patient’s life circumstance to the insurer. Routine medication access becomes an occasion for additional disclosure of vulnerability: housing status, substance use history, prior failures of adherence. The system positions this as helpful context that may speed approval. Structurally, it converts the act of refilling a prescription into an opportunity for institutional surveillance, with no clear use limitation on the information collected. The patient who wants the medication faster is offered the opportunity to disclose more. The patient who declines that disclosure is left in the standard timeframe, which is governed by the seventh-day clause.
Attrition as Filter
It is at this point somewhere between the diagnosis code field and the prior-treatment-outcome table that many patients stop. The form does not deny anyone. The plan does not refuse coverage. The medication remains formally accessible. What happens, instead, is that some percentage of eligible patients look at what compliance with the process would require and decide that the medication is not worth what it costs to obtain it.
This decision is not irrational. For a patient managing chronic illness, cognitive load, fluctuating symptoms, caregiving responsibilities, or the simple exhaustion of having done this many times before, the calculation is straightforward: the energy required to assemble the case file, follow up with the provider’s office, wait through a timeframe that may reset on the seventh day, and resubmit if information is deemed inadequate exceeds the energy available. The medication is forgone. The decision is read by the patient, in the moment, as a personal failure of perseverance — the inability to do what the system requires of them. It is not. It is the predictable response of a body operating under finite capacity to a process designed without reference to that capacity.
The attrition is not measured. There is no field on the form for patients who declined to pursue authorization. The system records denials and approvals. It does not record the population that exited before either outcome was reached. From the plan’s perspective, the cost reduction associated with non-pursuit is indistinguishable from the cost reduction associated with appropriate gatekeeping. Both produce the same line item.
Rationing Without Denial
What this design accomplishes is rationing that is not legible as rationing. No formulary was cut. No coverage was withdrawn. No eligibility category was narrowed. Audit reports will show that the plan continues to authorize the medications it was previously authorizing. The denial rate may even improve, because patients who would have been denied are filtered out before submission rather than after.
Friction-based rationing is structurally harder to challenge than denial-based rationing. There is no adverse decision to appeal. There is no notice of action to contest. There is only a process that some patients can complete and some patients cannot and the inability to complete is read by the system as the absence of need rather than the presence of a barrier. The legal framework for challenging benefit denials assumes a denial. The administrative workflow that produces this outcome does not generate one.
The shift in timeframes that took effect on April 1 does not, on its own, change the substance of what Independent Health covers. What it changes is the relationship between coverage and access. Coverage continues to mean what it meant. Access — the actual receipt of the medication, in time to be useful, without exhausting the resources required to function in the rest of one’s life increasingly depends on something the plan does not call by its name: administrative endurance.
That endurance is unevenly distributed. The patients who possess it are not the patients whose conditions necessarily require it most. The system does not adjust. It processes the gap as individual variation in how seriously people take their own care.
The form is not a request. The timeframe is not a deadline. The friction is not incidental. It is the policy.